02 August 2011

(S)-2-Amino-3-(3-phenylacetylimadazol-4-yl)propanoic acid

  • Rapid inhibition of difficult to treat cancer cell lines.
  • Reproducible cell viability/dose response curves.
  • Mechanism consistent with activation of apoptotic pathway.
  • Physico-chemical properties consistent with high oral absorption and BBB (Blood-brain barrier) permeability.
  • Pharmacokinetics, ADME (Absorption, Distribution, Metabolism, Excretion), likely simple and efficient.
  • Metabolism most probably through decarboxylation.
This new chemical entity (NCE) has been independently confirmed as effective against U-87 cell line (brain cancer, anaplastic astrocytoma - glioblastoma multiforme), HEP G2 cell line (liver cancer, hepatocellular carcinoma), A 375 cell line (human malignant melanoma). A wide therapeutic margin with no inhibition of D8 LCL 'B' cells (control - 'normal' bone marrow) - at concentrations used to inhibit neoplasms. There are 208 individual types of cancer - this compound is effective against all three types listed above and will most probably be effective against the remaining 205.

CRO toxicology, pre-IND meeting with FDA, human clinical trials (Phase I or Phase I/II hybrid) - as soon as $$$ are available. Let's save lives!
Contact me if you can be of assistance with finances to expedite this process. Thank you.


Dennis Wright